Healthcare & Life Sciences

Latham offers life sciences and healthcare industry leaders deep sector knowledge, legal expertise, and commercial and government insight to meet client needs.

Why Latham

Latham’s cross-disciplinary healthcare and life sciences team delivers insightful, practical guidance and sophisticated representation to a full spectrum of companies across the globe, on every type of transaction or dispute a company may face. Many of us hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.

We regularly navigate commercial and regulatory issues related to the Food and Drug Administration, the Patent Trial and Appeals Board, the European Medicines Agency, the European Commission, and other state, and federal agencies in the US and across Europe.

We deliver:

  • The right team. We work with companies at every stage of development, from fast-growing startups to mature public companies, in virtually every sector and subsector of the industry – including healthcare services, biotechnology, medtech and medical devices. With an outstanding global platform, we can scale our client teams to meet client needs — whether that means drawing on best-of-the-best capabilities in public company representation, M&A, capital markets, regulatory advice or IP and securities litigation.
  • Insight. Our broad client base and on-the-ground presence in the world’s healthcare and life sciences hubs afford us an expansive view of the commercial, scientific, regulatory, and political trends shaping the markets in which clients operate. We know how traditional regulatory regimes work, and quickly set the bar for successful strategies in dynamic and uncertain regulatory landscapes.
  • Results. By leveraging decades of experience and a culture of innovation, we have developed an impressive track record navigating many of the industry’s largest, most complex, and most consequential deals through commercial and regulatory issues, as well as winning precedent-setting litigation and trials.


Our Experience

Awards & Rankings

  • Healthcare & Life Sciences Counsel Named Among Top Healthcare Lawyers in California - November 07, 2021
  • Intellectual Property Litigation Practice Honored at National Law Journal’s Professional Excellence Awards - October 24, 2021
  • Latham Honored at National Law Journal’s Professional Excellence Awards - October 24, 2021
  • Latham Honored With Three Accolades By The Deal Awards 2021 - September 29, 2021
  • Latham Honored With Four Notable Life Science Awards - September 26, 2021

A best-in-market corporate team with a sterling reputation for its counsel on M&A transactions, public and private securities offerings, and strategic partnerships. Acts for early-stage and long-established companies as well as banks and financiers. Contentious practice with expertise in handling everything from white-collar investigations to intellectual property disputes. 

Chambers 2020 USA


Private Equity and Healthcare: Enforcement Trends and Investor RiskWebcast – FDA Regulatory Updates and 2020 Outlook for Vaping and Cannabis-Derived Substances

Media Coverage

United Therapeutics Beats HHS’ Discount-Dodging ClaimsLitigator of the Week Runners-Up and Shout OutsFederal Circuit Axes Philips Heart Monitor Patent Under Alice


Latham & Watkins Advises P3 Health Partners in Completed Business Combination with Foresight Acquisition Corp.Latham & Watkins Advises Summit Partners on Sale of RadioOnkologieNetzwerk Latham & Watkins Advises Baird Capital and Endeavour Vision on Virtual Incision Corporation’s Funding Round

Thought Leadership

Healthcare & Life Sciences: Drug Pricing DigestMHRA Seeks New Regulatory Regime for Medical Devices, DiagnosticsHealthcare & Life Sciences: Drug Pricing Digest

Webcasts & Podcasts

Telehealth Innovations: Legal Considerations for Digital Health Companies Engaging in Value-Based CareThe Biden Administration’s Regulatory and Enforcement Priorities: A Six-Month UpdateDrug and Device Pricing and Reimbursement Landscape: Legal and Policy Trends Under the Biden Administration